Vaxcyte Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Vaxcyte
PCVX Stock  USD 59.82  2.16  3.48%   
Vaxcyte's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vaxcyte's valuation are provided below:
Gross Profit
-75 M
Market Capitalization
9 B
Earnings Share
(4.85)
We have found one hundred twenty available fundamental trend indicators for Vaxcyte, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vaxcyte current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 4.1 B in 2026. Enterprise Value is likely to drop to about 3.9 B in 2026
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 125.7 M, Depreciation And Amortization of 26.1 M or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.83. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Build AI portfolio with Vaxcyte Stock
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Vaxcyte Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.2 B3 B784.7 M
Slightly volatile
Short and Long Term Debt Total240.3 M228.8 M38.9 M
Slightly volatile
Other Current Liabilities135.2 M128.7 M33 M
Slightly volatile
Total Current Liabilities216 M205.8 M51.5 M
Slightly volatile
Other Liabilities7.7 K8.1 K142 K
Slightly volatile
Property Plant And Equipment Net516.3 M491.7 M87.7 M
Slightly volatile
Accounts Payable74.4 M70.9 M16.2 M
Slightly volatile
Cash294.6 M174 M174 M
Slightly volatile
Non Current Assets Total1.5 B1.4 B300.8 M
Slightly volatile
Non Currrent Assets Other482.6 K508 K7.1 M
Slightly volatile
Other Assets1.091.15866.5 K
Pretty Stable
Long Term Debt384.8 K405 K2.2 M
Slightly volatile
Cash And Short Term Investments1.6 B1.6 B470.9 M
Slightly volatile
Common Stock Shares Outstanding70.8 M136.1 M39.7 M
Slightly volatile
Long Term Debt Total384.8 K405 K2.2 M
Slightly volatile
Liabilities And Stockholders Equity3.2 B3 B784.7 M
Slightly volatile
Non Current Liabilities Total162.4 M154.7 M43.9 M
Slightly volatile
Capital Surpluse703.8 M670.3 M250.5 M
Slightly volatile
Other Current Assets20.8 M19.8 M6 M
Slightly volatile
Other Stockholder Equity5.1 B4.8 B1.1 B
Slightly volatile
Total Liabilities378.5 M360.5 M95.4 M
Slightly volatile
Total Current Assets1.7 B1.6 B483.9 M
Slightly volatile
Short Term Debt4.3 M6.1 M2.5 M
Slightly volatile
Common Stock69.8 K134 K40.2 K
Slightly volatile
Property Plant Equipment38.2 M36.4 M14.1 M
Slightly volatile
Common Stock Total Equity33.8 K64.4 K25.7 K
Slightly volatile
Capital Stock77.7 K134 K40.6 K
Slightly volatile
Non Current Liabilities Other85.5 K90 K1.8 M
Slightly volatile
Net Working Capital770.3 M1.4 B403.1 M
Slightly volatile
Net Receivables48.9 M46.6 M7.3 M
Slightly volatile
Property Plant And Equipment Gross550.7 M524.5 M101.3 M
Slightly volatile
Deferred Long Term Liabilities403.3 K575 K239.9 K
Slightly volatile

Vaxcyte Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income125.7 M119.7 M25.3 M
Slightly volatile
Depreciation And Amortization26.1 M24.9 M5.8 M
Slightly volatile
Selling General Administrative135.8 M129.4 M32.6 M
Slightly volatile
Other Operating Expenses969.9 M923.7 M210.9 M
Slightly volatile
Research Development834 M794.3 M172.8 M
Slightly volatile
Total Operating Expenses969.9 M923.7 M210.8 M
Slightly volatile
Total Other Income Expense Net164.9 M157 M30.6 M
Slightly volatile
Net Interest Income125.7 M119.7 M25.6 M
Slightly volatile
Cost Of Revenue16.6 M18.2 M8.7 M
Slightly volatile
Reconciled Depreciation26.1 M24.9 M6 M
Slightly volatile
Non Operating Income Net Other2.2 M4.1 M1.5 M
Slightly volatile
Selling And Marketing Expenses8.1 M9.2 M10 M
Slightly volatile

Vaxcyte Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.7 M1.8 M27.5 M
Slightly volatile
Stock Based Compensation145.8 M138.8 M27.1 M
Slightly volatile
Begin Period Cash Flow273.8 M389.2 M147.9 M
Slightly volatile
Other Cashflows From Financing Activities1.9 M2 M14.3 M
Pretty Stable
Depreciation26.1 M24.9 M5.5 M
Slightly volatile
Capital Expenditures14.7 M13.7 M8 M
Slightly volatile
Total Cash From Financing Activities1.9 M2 M261.8 M
Slightly volatile
End Period Cash Flow290.9 M175.4 M157.1 M
Slightly volatile
Change To Account Receivables853.6 K781.2 K1.1 M
Slightly volatile
Dividends Paid299.2 K336.6 K367.4 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.520.55161.8129
Very volatile
Payables Turnover0.05150.05420.2356
Slightly volatile
Cash Per Share13.8111.470111.6314
Slightly volatile
Days Payables Outstanding7.3 K7 K3.7 K
Slightly volatile
Income Quality0.970.85510.8796
Very volatile
Current Ratio8.247.90949.4505
Pretty Stable
Capex Per Share0.180.10080.1309
Slightly volatile
Interest Debt Per Share1.771.68150.8962
Pretty Stable
Debt To Assets0.04240.07510.0704
Slightly volatile
Days Of Payables Outstanding7.3 K7 K3.7 K
Slightly volatile
Ebt Per Ebit1.00.830.9364
Slightly volatile
Long Term Debt To Capitalization0.08150.04580.0749
Slightly volatile
Quick Ratio8.247.90949.4505
Pretty Stable
Cash Ratio0.80.84557.1404
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.851.02091.0588
Slightly volatile
Debt Ratio0.04240.07510.0704
Slightly volatile

Vaxcyte Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.1 B6.3 B2.8 B
Slightly volatile
Enterprise Value3.9 B6.3 B2.7 B
Slightly volatile

Vaxcyte Fundamental Market Drivers

Vaxcyte Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-107.7 M-102.3 M
Cost Of Revenue18.2 M16.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY